Freeline Bags Alnylam's Heggie As CEO
Hemophilia B Gene Therapy Advances
Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.
